Follow us on X
Follow us on LinkedIn
Latest News

In Her New Role as Director of the GENYO Institute, 3TR Coordinator Dr Alarcón Riquelme Presents the Project at the First Bio Med & Tech Talks in Granada

3TR congratulates Dr Marta Alarcón Riquelme on her recent promotion within the Centre for Genomics and Oncology Research (GENYO), funded by Pfizer, University of Granada-Junta de Andalucía. Since 11 March, the 3TR project coordinator is the scientific director of the institute in Granada, having previously been head of the genomic medicine department and deputy director of the institute. Commenting on her appointment, Dr Alarcón Riquelme said: ”I am excited and honoured to take on this new role at the centre. My commitment is to continue fostering a collaborative research environment and to promote and secure our future together.”

During International Health Week following World Health Day, Alarcón Riquelme, in her new position as GENYO Director, immediately took on a prominent role at the first Bio Med & Tech Talks from 8 to 11 April in Granada. The multidisciplinary high-level event on biomedicine and biotechnology aims to give greater visibility to regional, national and international advances in research, laboratory facilities and healthcare professionals. A particular focus is on the host region of Andalusia, which is also home to the GENYO institute.

In a 20-minute interview session on 9 April at the Hospital Clínico Universitario San Cecilio in Granada, the 3TR coordinator reported on the work of the GENYO centre in general and the objectives and research approaches of 3TR in particular. ”Around 30 to 40 per cent of patients hardly respond to existing therapies,” said Marta Alarcón Riquelme, which is why 3TR is researching the molecular basis of seven different immune-induced disorders in an integrated approach in order to find common treatment options and provide relief for patients with autoimmune, inflammatory and allergic diseases. The central question in 3TR, but also at the Institute of Genomics and Oncological Research, is whether patients with different diseases – regardless of their clinical diagnosis – can receive the same treatment in the future due to common pathogen-associated molecular patterns.

Announcement of the interview with Dr Marta Alarcón Riquelme (GENYO) at the first 'Bio Med & Tech Talk' in Granada

Dr Marta Alarcón Riquelme presents her work at GENYO and in 3TR to the expert audience